DK1528934T3 - Anvendelse af antistoffer mod et tumorassocieret antigen - Google Patents
Anvendelse af antistoffer mod et tumorassocieret antigen Download PDFInfo
- Publication number
- DK1528934T3 DK1528934T3 DK03783820.8T DK03783820T DK1528934T3 DK 1528934 T3 DK1528934 T3 DK 1528934T3 DK 03783820 T DK03783820 T DK 03783820T DK 1528934 T3 DK1528934 T3 DK 1528934T3
- Authority
- DK
- Denmark
- Prior art keywords
- tumor
- antibody
- use according
- cells
- tumor cells
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. Anvendelse af et præparat på basis af et antistof rettet mod en Lewis Y til fremstilling af et lægemiddel til intraoperativ behandling af tumorpatienter ved immunkompleksering af tumorceller inden for rammen af kirurgiske indgreb, hvorved præparatet anvendes til profylaktisk behandling for at forhindre spredning af tumorceller, og hvorved tumorcellen er en epitelial tumorcelle, og hvorved lægemidlet administreres umiddelbart under eller indenfor 24 timer, før det kirurgiske indgreb finder sted.
2. Anvendelse ifølge krav 1, kendetegnet ved, at antistoffet anvendes i en antistofblanding af forskellige antistoffer med specificitet for tumorassocierede antigener.
3. Anvendelse ifølge krav 1 eller 2, kendetegnet ved, at antistoffet funktionelt aktiverer immunsystemet i overensstemmelse med en ADCC og CDC-effektorfunktion.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved, at antistoffet binder på Lewis Y med en affinitet svarende til en dissociationskonstant under en Kd-værdi på 1CT6 mol/1, fortrinsvis mindre end 1CT7 mol/1 og mest foretrukket 1CT8 mol/1 eller mindre.
5. Anvendelse ifølge et hvilket som helst af kravene 1 til 4, kendetegnet ved, at antistoffet er afledt af murine, kimære, humaniserede og/eller humane kilder.
6. Anvendelse ifølge et hvilket som helst af kravene 1 til 5, kendetegnet ved, at lægemidlet anvendes systemisk med en engangsdosis på mindst 50 mg, fortrinsvis mindst 100 mg, og mest foretrukket på 200 mg, op til 2 g per patient.
7. Anvendelse ifølge et hvilket som helst af kravene 1 til 6, kendetegnet ved, at lægemidlet applikeres lokalt på tumorvævet og/eller sårområdet.
8. Anvendelse ifølge et hvilket som helst af kravene 1 til 7, kendetegnet ved, at lægemidlet administreres indenfor 4 timer før det kirurgiske indgreb finder sted.
9. Anvendelse ifølge et hvilket som helst af kravene 1 til 8, kendetegnet ved, at det kirurgiske indgreb foretages for biopsi og/eller fjernelse af en fast tumor.
10. Anvendelse ifølge et hvilket som helst af kravene 1 til 9, kendetegnet ved, at det kirurgiske indgreb foretages for at bestemme en tumors malignitet.
11. Anvendelse ifølge et hvilket som helst af kravene 1 til 10, kendetegnet ved, at antistoffet bestemmes på immunkomplekseret tumorvæv efter det kirurgiske indgreb.
12. Anvendelse ifølge et hvilket som helst af kravene 1 til 11, kendetegnet ved, at antistoffet bestemmes på tumorceller i blod- og serumprøver.
13. Præparat baseret på et antistof rettet mod en Lewis Y til anvendelse i en intraoperativ behandling af tumorpatienter ved immunkompleksering af tumorceller inden for rammen af kirurgiske indgreb, hvorved præparatet anvendes til profylaktisk behandling for at forhindre spredning af tumorceller, og hvorved tumorcellen er en epitelial tumorcelle, og hvorved lægemidlet administreres direkte under eller indenfor 24 timer, før det kirurgiske indgreb finder sted
14. Præparat til anvendelse ifølge krav 13, hvor anvendelsen yderligere er defineret i et hvilket som helst af kravene 2 til 12.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0121702A AT413487B (de) | 2002-08-12 | 2002-08-12 | Verwendung von antikörpern gegen ein tumor-assoziiertes antigen |
| PCT/AT2003/000219 WO2004014421A1 (de) | 2002-08-12 | 2003-07-31 | Verwendung von antikörpern gegen ein tumor-assoziiertes antigen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1528934T3 true DK1528934T3 (da) | 2015-04-13 |
Family
ID=31499792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03783820.8T DK1528934T3 (da) | 2002-08-12 | 2003-07-31 | Anvendelse af antistoffer mod et tumorassocieret antigen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060127403A1 (da) |
| EP (1) | EP1528934B1 (da) |
| AT (1) | AT413487B (da) |
| AU (1) | AU2003250570B2 (da) |
| CA (1) | CA2494319A1 (da) |
| DK (1) | DK1528934T3 (da) |
| ES (1) | ES2534419T3 (da) |
| WO (1) | WO2004014421A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2033657A1 (de) | 2007-09-04 | 2009-03-11 | Trion Pharma Gmbh | Intraoperative trifunktionale Antikörper-Applikation zur Prophylaxe intraperitonealer Tumorzelldissemination |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4643971A (en) * | 1983-03-11 | 1987-02-17 | Sloan-Kettering Institute | Monoclonal antibodies to human bladder and ureter cancers and method |
| DE69230545T2 (de) | 1991-08-21 | 2000-07-06 | Novartis Ag, Basel | Antikörperderivate |
| US6096289A (en) * | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| WO1993021940A1 (en) * | 1992-05-06 | 1993-11-11 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| AU6445894A (en) * | 1993-03-19 | 1994-10-11 | Duke University | Method of treatment of tumors with an antibody binding to tenascin |
| US6495129B1 (en) * | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
| US5792456A (en) * | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| US6107102A (en) * | 1995-06-07 | 2000-08-22 | Regents Of The University Of California | Therapeutic microdevices and methods of making and using same |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| AU782325B2 (en) * | 1999-05-14 | 2005-07-21 | Genentech Inc. | Treatment with anti-ErbB2 antibodies |
| WO2001003738A1 (fr) * | 1999-07-07 | 2001-01-18 | Hiroshi Maeda | Agents de type polymeres destines a la prevention de metastases et de la recurrence du cancer et methode de prevention de metastases et de la recurrence du cancer |
| DE19947559A1 (de) * | 1999-09-24 | 2001-04-19 | Schering Ag | Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung |
| US6949342B2 (en) * | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
| AT413486B (de) | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| US20040142381A1 (en) * | 2002-07-31 | 2004-07-22 | Hubbard Stevan R. | Methods for designing IGF1 receptor modulators for therapeutics |
-
2002
- 2002-08-12 AT AT0121702A patent/AT413487B/de not_active IP Right Cessation
-
2003
- 2003-07-31 US US10/524,520 patent/US20060127403A1/en not_active Abandoned
- 2003-07-31 WO PCT/AT2003/000219 patent/WO2004014421A1/de not_active Application Discontinuation
- 2003-07-31 ES ES03783820.8T patent/ES2534419T3/es not_active Expired - Lifetime
- 2003-07-31 CA CA002494319A patent/CA2494319A1/en not_active Abandoned
- 2003-07-31 EP EP03783820.8A patent/EP1528934B1/de not_active Expired - Lifetime
- 2003-07-31 DK DK03783820.8T patent/DK1528934T3/da active
- 2003-07-31 AU AU2003250570A patent/AU2003250570B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1528934A1 (de) | 2005-05-11 |
| EP1528934B1 (de) | 2015-01-07 |
| ATA12172002A (de) | 2005-08-15 |
| CA2494319A1 (en) | 2004-02-19 |
| ES2534419T3 (es) | 2015-04-22 |
| AU2003250570A1 (en) | 2004-02-25 |
| AT413487B (de) | 2006-03-15 |
| US20060127403A1 (en) | 2006-06-15 |
| AU2003250570B2 (en) | 2009-10-22 |
| WO2004014421A1 (de) | 2004-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10487150B2 (en) | SIRP alpha-antibody fusion proteins | |
| US20230110249A1 (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| JP7342701B2 (ja) | 癌の治療及び／又は予防用医薬組成物 | |
| US20160000914A1 (en) | Combination of tumor-associated surface protein antigens and tumor-associated sugars in the treatment and diagnosis of cancer | |
| JP4854912B2 (ja) | 癌に対する抗体 | |
| JP6581572B2 (ja) | 補体因子ｈ阻害薬 | |
| KR20100016237A (ko) | 항-ＥｐＣＡＭ 항체 및 이의 용도 | |
| AU2010203050B2 (en) | Preparation based on an antibody directed against a tumor-associated glycosylation such as Lewis structures | |
| WO2005018671A1 (ja) | 癌転移阻害剤 | |
| Durrant et al. | A new anticancer glycolipid monoclonal antibody, SC104, which directly induces tumor cell apoptosis | |
| DK1528934T3 (da) | Anvendelse af antistoffer mod et tumorassocieret antigen | |
| JP4826697B2 (ja) | 個別化抗ガン抗体 | |
| BR112019020507A2 (pt) | agente de alvejamento de erbb-2 e um anticorpo bispecífico com locais de ligação de antígenos que ligam um epítopo em uma parte extracelular de erbb-2 e erbb-3 para tratamento de um indivíduo com um tumor positivo erbb-2, erbb-2 / erbb-3 | |
| WO2023076783A1 (en) | Antibody binding to chi3l1 for treating cancer | |
| CN115814076A (zh) | 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用 |